News & Updates
Filter by Specialty:
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
Adding sodium–glucose co-transporter-2 (SGLT2) inhibitors to usual care in the treatment of hospitalized patients with COVID-19 does not necessarily lead to improved survival, according to the results of a meta-analysis.
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
15 Sep 2024
Diabetes, insulin use up risk of death, cardiac events in AF patients
In patients with atrial fibrillation (AF), being diabetic contributes to an increased risk of all-cause death, cardiovascular disease (CVD), myocardial infarction (MI), major bleeding, and major adverse cardiovascular events (MACE), results of the GLORIA-AF study have shown.
Diabetes, insulin use up risk of death, cardiac events in AF patients
14 Sep 2024
High leptin levels linked to lower risk of Alzheimer’s disease
A study has recently observed the possible protective effect of leptin against the development of Alzheimer’s disease (AD) by improving insulin sensitivity.
High leptin levels linked to lower risk of Alzheimer’s disease
09 Sep 2024
Vitamin D deficiency tied to higher T2D risk
Increased serum concentration of 25(OH)D appears to contribute to a reduced risk of type 2 diabetes (T2D) across the glycaemic spectrum below the threshold for diabetes, reports a study. Improving the lipid profile may be partly responsible for the favourable association.
Vitamin D deficiency tied to higher T2D risk
09 Sep 2024
SGLT-2 inhibitors may prevent dementia in adults with T2D
Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.